Nurix Therapeutics Reports Disappointing Q2 Financial Results

Thursday, 11 July 2024, 20:21

Nurix Therapeutics reported their Q2 earnings, with GAAP EPS of -$0.71 missing estimates by $0.08. Revenue stood at $12.09M, falling short by $9.69M. Despite the disappointing numbers, the company maintains a strong cash position.
LivaRava Finance Meta Image
Nurix Therapeutics Reports Disappointing Q2 Financial Results

Nurix Therapeutics Q2 Earnings Update

Nurix Therapeutics recently released their Q2 financial results, revealing a miss on both EPS and revenue.

Key Findings:

  • GAAP EPS: The company reported a loss of -$0.71, missing estimates by $0.08.
  • Revenue: Nurix generated $12.09M in revenue, which fell short by $9.69M.
  • Cash Position: Despite the poor performance, Nurix maintains a strong cash position.

Overall, Nurix Therapeutics faces challenges in meeting financial expectations in Q2, but continues to hold a solid financial footing.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe